{"id":"metformin-xr-plus-liraglutide","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Nausea"},{"rate":"5-15","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"15-30","effect":"Gastrointestinal distress"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Hypoglycemia"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:33:14.747865","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, primarily through AMPK activation. Liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, and slows gastric emptying. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"Metformin XR reduces hepatic glucose production and improves insulin sensitivity, while liraglutide stimulates insulin secretion and reduces glucagon in a glucose-dependent manner via GLP-1 receptor activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:01.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["modality→Peptide"],"trialDetails":[{"nctId":"NCT05952882","phase":"PHASE3","title":"Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility","status":"UNKNOWN","sponsor":"Mỹ Đức Hospital","startDate":"2023-11-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":188},{"nctId":"NCT01234649","phase":"PHASE3","title":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08-11","conditions":"Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome","enrollment":153},{"nctId":"NCT02492763","phase":"PHASE2","title":"A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-27","conditions":"Type II Diabetes Mellitus","enrollment":176},{"nctId":"NCT01296412","phase":"PHASE3","title":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-11","conditions":"Diabetes Mellitus, Type 2","enrollment":653}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Victoza"],"phase":"phase_3","status":"active","brandName":"Metformin XR plus liraglutide","genericName":"Metformin XR plus liraglutide","companyName":"Woman's","companyId":"woman-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin XR reduces hepatic glucose production and improves insulin sensitivity, while liraglutide stimulates insulin secretion and reduces glucagon in a glucose-dependent manner via GLP-1 receptor activation. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}